<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>9235098</identifier>
<setSpec>0212-7199</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Villalba Garciá, M V</dc:author>
<dc:author>Muiño Miguez, A</dc:author>
<dc:author>Segado Soriano, A</dc:author>
<dc:author>Millan Núñez-Cortés, J</dc:author>
<dc:author>López Gonzalez-Cobos, C</dc:author>
<dc:author>Gil Gómez, J</dc:author>
<dc:description xml:lang="en">Neuroleptic Malignant Syndrome (NMS) is a rare disease characterized by hyperthermia, altered level of consciousness, autonomic dysfunction and muscular rigidity in relation to treatment with different drugs. We describe ten patients with Neuroleptic Malignant Syndrome in our Hospital. The mean age was 48 +/- 18 and females were majority (70%). Haloperidol, alone or with another farms, was relation with NMS in the 90% of the cases. Mortality became the 20% and it was relation with respiratory failure and delayed on admission in Intensive Care Unit (UCI). We remarked the importance to have a high suspicious index for attending of this disease by a precocious and intensive treatment.</dc:description>
<dc:type>English Abstract</dc:type>
<dc:language>es</dc:language>
<dc:date>1997 May </dc:date>
<dc:title xml:lang="es">Síndrome neuroléptico maligno.</dc:title>
<dc:title xml:lang="en">[Malignant neuroleptic syndrome].</dc:title>
<dc:publisher>Anales de medicina interna (Madrid, Spain : 1984)</dc:publisher>
</metadata>
</record>
</pubmed-document>
